University of Cambridge, Elan launch translational research center; Micromet starts mid-stage blinatumomab trial;

 @FierceBiotech: Activist investor pursues alternative strategies for Par Pharma. News | Follow @FierceBiotech

 @RyanMFierce: GE is pumping another $300M into radiation-dose management tech. Release | Follow @RyanMFierce

 @MaureenFierce: UK switches to Merck's Gardasil for HPV vaccination. Item | Follow @MaureenFierce

> The University of Cambridge and Elan have launched the Cambridge-Elan Centre for Research Innovation and Drug Discovery. Researchers at the center will focus on translational research for Alzheimer's and Parkinson's diseases.Release

> Lawrenceville, NJ-based Celsion ($CLSN) saw its shares fall on news that its phase III trial of liver cancer therapy Thermodox will continue to a final analysis in late 2012. Report

> Micromet has started a Phase II trial of blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Micromet release

> OXiGENE has inked a purchase agreement for the sale of up to $20 million of its common stock with Lincoln Park Capital Fund. Proceeds will help fund the company's pipeline work. Report

> Researchers at the Methodist Cancer Center in Houston are examining the efficacy and safety of chloroquine, a 60-year-old malaria drug, a possible treatment for patients with advanced or metastatic breast cancer. Release

Pharma News

 @FiercePharma: Ranbaxy on verge of settling with FDA for $400M, an Indian paper reports--which means its Lipitor copy might launch.More | Follow @FiercePharma

> NICE votes nay for Lucentis, cancer meds; yea for Eliquis. Report

> Merck chair looks back over 40-year career at company. Report

> Supreme Court will hear sales-rep overtime dispute. News

> Ranbaxy said to wrap up FDA woes with $400M settlement. Article

Medical Device News

> ArthroCare to pay $74M to settle class action. Story

> Fujifilm to begin trial of 3-D digital mammography tech. News

Biotech IT News

> Roche, BGI team on new capture tech for genetics studie. Article

> Mining data on FDA-OK'd drugs leads to potential cancer treatment. Story

> GNS Healthcare CEO launches Forbes blog. News

And Finally... Researchers at Harvard University have conducted a study that suggests a combination of an antibiotic and a synthetic version of the protein BPI could prevent illness in people who've been exposed to high levels of radiation. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.